


Pharmasolutions


SPI provides our know-how and laboratory capabilities to assist your development on a fee for service basis. SPI acknowledges that manufacturing in your equipment may yield different results. Choose from the list below, or collaborate with us on your next innovation!


Active Ingredients	API	Dosage Form	Strengths	Tablet Weights	Excipients	Stability Data	Reference Product	Comparison Data	License Available	
Tadalafil	Base Ph. Eur	ODT	20mg	200mg	Pharmaburst® 500 Lubripharm® SSF	N/A	Cialis®	Dissolution Similarity Rate	Worldwide except MENA ³	
Ondansetron	Base USP	ODT	4mg 8mg	150mg 300mg	Pharmaburst® C1 Lubripharm® SSF	40/75 - 3 mos	Zofran ODT®	Dissolution Similarity Factor	Worldwide	
Carbidopa/ Levodopa	Both USP	ODT	10/100mg 25/100mg 25/250mg	399mg 398mg 998mg	Pharmaburst® C1 Lubripharm® SSF Mannogem® Mannitol	25/60 - 6 mos 30/65 - 6 mos 40/75 - 6 mos	Parcopa	Dissolution Similarity Factor	Worldwide except US, Canada, Mexico	
Rizatriptan	Benzoate USP	ODT	5mg 10mg	150mg 300mg	Pharmaburst® C1	40/75 - 3 mos	Maxalt-MLT®	Dissolution Similarity Factor	worldwide except US, Canada, Mexico	
Acetaminophen	Taste masked IH	ODT	250mg 160mg 125mg 80mg	900mg 576mg 450mg 288mg	Pharmaburst® 500 Lubripharm® SSF Actimask® Acetaminophen	25/60 - 12 mos 30/65 - 12 mos 40/75 - 6 mos	Tylenol®	Dissolution Similarity Factor	Worldwide	
Nicotine ¹	Nicotine Polacrilex USP	Lozenge	2mg 4mg	1200mg 1200mg	Mannogem® NL Effer-Soda® 12 Lubripharm® SSF	25/60 - 12 mos 40/75 - 6 mos	Commit® Lozenge	Dissolution Similarity Factor	Worldwide except US, Canada, Mexico, EPO ²	
Loratadine	Base	ODT	5mg 10mg	150mg 300mg	Pharmaburst® C1	25/60 - 6 mos 30/65 - 6 mos 40/75 - 6 mos	Claritin® Reditab®	Dissolution Similarity Factor	Worldwide	
Phloroglucinol	Dihydrate Ph. Eur	ODT	80mg	400mg	Pharmaburst® B1	25/60 - 3 mos 30/65 - 3 mos 40/75 - 3 mos	Spasfon Lyoc	Dissolution Rate	Worldwide	
Domperidone	Ph. Eur	ODT	10mg	300mg	Pharmaburst® B1 Lubripharm® SSF	25/60 - 6 mos 30/65 - 6 mos 40/75 - 6 mos	Motilyo® Lyophilisat	Dissolution Rate	Worldwide	
Mirtazapine	USP	ODT	15mg	300mg	Pharmaburst® C1 Lubripharm® SSF	25/60 - 3 mos 30/65 - 3 mos 40/75 - 3 mos	Remeron SolTab	Dissolution Rate	Worldwide	
Risperidone	Benzoate	ODT	2mg	500mg	Pharmaburst® B1 Lubripharm® SSF	25/60 - 3 mos 40/75 - 3 mos	Resperdal® M-tab®	Dissolution Rate	Worldwide	
Loperamide	HCl USP/ EP	ODT	2mg	200mg	Pharmaburst® B1	25/60 - 3 mos 30/65 - 3 mos 40/75 - 3 mos	Imodium® Capsule (Europe)	Imodium® Quick Dissolve (Canada)	Dissolution Similarity Factor	Worldwide except Europe ⁴

- 1 Data package includes pilot PK study data and information for facilitating development of a commercial ODT product.
- 2 European Patent Organization as of July 2012: Albania, Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Latvia, Monaco, Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Sweden, Slovenia, Slovakia, San Marino, Turkey.
- 3 MENA Territory: Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, UAE, Oman, Iraq, Jordan, Lebanon, Palestine, Egypt, Libya, Tunisia, Algeria and Morocco.
- 4 European Union as of Dec 2006: Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, United Kingdom




Pharmasolutions






Innovative




Specializing in
Patient Friendly Dosage Forms

Experience



- Material & Formulation Expertise**
- ➔ **Skilled Development Scientists in US & India**
- ➔ **Track Record of Success**

Possibilities






- Extend Lifecycle**
- Reduce Trial & Error**
- Speed Development**




Get to Market Faster

Simple

Flexible

Pay for Success

 SPI Pharma
 salesinfo@spipharma.com
 @spipharma_real

 @spipharma
 www.spipharma.com
 SPI Pharma








All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties.

SPI PHARMA EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, CURRENCY, COMPLETENESS AND/OR THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY INFORMATION CONTAINED IN THIS BROCHURE AND/OR ANY PRODUCT DESCRIBED OR PROMOTED IN THIS BROCHURE, INCLUDING WARRANTIES WITH RESPECT TO INFRINGEMENT OF ANY PATENT, COPYRIGHT, OR OTHER RIGHTS OF A THIRD PARTY. We reserve the right to change product specification and not specified properties of the products without prior notice.